Lynda D. Roman

Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

Agustin A. García, Hal W. Hirte, Gini F. Fleming et al. · Journal of Clinical Oncology · 2007 · 547 citations

Phase II Trial of Bevacizumab in the Treatment of Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

Bradley J. Monk, Michael W. Sill, Robert A. Burger et al. · Journal of Clinical Oncology · 2009 · 341 citations · Full text

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.

Laila I. Muderspach, Sharon P. Wilczynski, Lynda D. Roman et al. · PubMed · 2000 · 311 citations

Vulvar Intraepithelial Neoplasia, Immunology, Gynecology +23

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

Michael S. Gordon, Daniela Matei, Carol Aghajanian et al. · Journal of Clinical Oncology · 2006 · 249 citations

Cervical cancer in pregnancy: Reporting on planned delay in therapy

B. Duggan, Laila I. Muderspach, Lynda D. Roman et al. · International Journal of Gynecology & Obstetrics · 1994 · 211 citations